Vimarsana
Biggest News Aggregation in the World

Page 7 - Open Label Study News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Open Label Study. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Open Label Study Today - Breaking & Trending Today

Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual Meeting - Vimarsana News

Seres Therapeutics and Nestlé Health Science Present Results from ECOSPOR IV Phase 3 Study of VOWST™, a Microbiota-Based Oral Therapeutic for Prevention of Recurrence of C. Difficile Infection, at the Digestive Disease Week (DDW) Annual Meeting

Published: May 8, 2023

CAMBRIDGE, Mass. & HOBOKEN, N.J.--(BUSINESS WIRE)--May 8, 2023--

Source: cadillacnews.com
Related Topics:
United StatesUnited KingdomLindsay YanekCarlo TanziUs Bureau Of Labor StatisticsHealth ScienceAimmune Therapeutics IncSociety For Surgery Of The Alimentary TractExchange CommissionCenters For DiseaseUs Bureau Of Labor StatisticsUrgent Health ThreatAmerican Gastroenterological AssociationDrug AdministrationAmerican Society For Gastrointestinal EndoscopySeres Therapeutics IncDisease WeekAnnual MeetingChief Medical OfficerBreakthrough TherapyOrphan Drug DesignationsNew England JournalClinical ResponseInvestigational Oral Microbiome TherapeuticLabel Trial
BioVie's degenerative dementia drug candidate to be presented at the 78th Annual Scientific Convention of the Society of Biological Psychiatry. - Vimarsana News

BioVie's degenerative dementia drug candidate to be presented at the 78th Annual Scientific Convention of the Society of Biological Psychiatry.

Published: April 20, 2023

BioVie Inc (NASDAQ:BIVI) announced Thursday that a data abstract from its Phase 2 open-label trial of its degenerative dementia drug candidate has been...

Source: proactiveinvestors.com
Related Topics:
United StatesSan DiegoAndrew KesselAmerican Academy Of Neurology Annual MeetingBiovie IncAnnual Scientific ConventionMultimodal OutcomesOpen Label StudyCognitive Decline DueDegenerative DementiasNeurology Annual Meeting
Investegate |COMPASS Pathways Announcements | COMPASS Pathways: COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP - Vimarsana News

Investegate |COMPASS Pathways Announcements | COMPASS Pathways: COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP

Published: December 8, 2022

Investegate announcements from COMPASS Pathways, COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP

Source: investegate.co.uk
Related Topics:
United KingdomUnited StatesLa JollaCity OfEast SussexDavid FeifelSheppard Pratt BaltimoreStephen SchultzAmy LawrenceSheppard PrattScott AaronsonPsychiatric SciencesInstitute For Advanced DiagnosticsDrug AdministrationKadima Neuropsychiatry InstituteOther Common Mental Disorders Global HealthNational Institute Of Mental HealthExchange CommissionMeeting Of The American College NeuropsychopharmacologyAnnual MeetingAmerican CollegeDepression Rating ScaleChief Science OfficerAdvanced DiagnosticsPrincipal Investigator
COMPASS Pathways: COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP - Vimarsana News

COMPASS Pathways: COMP360 psilocybin therapy shows potential in open-label study in type II bipolar disorder presented at ACNP

Published: December 8, 2022

12 out of 14 patients went into remission for three months following a single 25mg dose of COMP360 psilocybin therapy, in an independent investigator-initiated, exploratory open-label study of type II

Source: finanznachrichten.de
Related Topics:
City OfUnited KingdomUnited StatesLa JollaEast SussexDavid FeifelSheppard Pratt BaltimoreStephen SchultzAmy LawrenceSheppard PrattScott AaronsonInstitute For Advanced DiagnosticsKadima Neuropsychiatry InstituteExchange CommissionNational Institute Of Mental HealthMeeting Of The American College NeuropsychopharmacologyAnnual MeetingAmerican CollegeDepression Rating ScaleChief Science OfficerAdvanced DiagnosticsPrincipal InvestigatorNew England JournalGuy GoodwinChief Medical Officer
SK life science Presents Latest Data on XCOPRI® (cenobamate tablets) CV in Adults with Partial-Onset (Focal) Seizures at the AES 2022 Annual Meeting - Vimarsana News

SK life science Presents Latest Data on XCOPRI® (cenobamate tablets) CV in Adults with Partial-Onset (Focal) Seizures at the AES 2022 Annual Meeting

Published: December 2, 2022

/PRNewswire/ -- SK Life Science, Inc., a subsidiary of SK Biopharmaceuticals Co., Ltd., an innovative global pharmaceutical company focused on developing...

Source: prnewswire.com
Related Topics:
United StatesUnited KingdomAngelini PharmaPrnewswire Sk Life Science IncSk GroupSource Sk Life Science IncSk Biopharmaceuticals Co LtdAmerican Epilepsy SocietyEpilepsy FoundationSk IncSk Life Science IncEuropean UnionSudden Unexpected DeathAnnual MeetingResponder Rates OverOno PharmaceuticalIgnis TherapeuticsGreater ChinaFamilial ShortNorth American Antiepileptic DrugPost Hoc AnalysisOpen Label StudyEpilepsy DuringCenobamate Clinical Development ProgramWho Gets